Welcome to our dedicated page for Quantum-Si Incorporated news (Ticker: QSI), a resource for investors and traders seeking the latest updates and insights on Quantum-Si Incorporated stock.
Quantum-Si Incorporated (Nasdaq: QSI) is a proteomics technology and life sciences company focused on single-molecule protein analysis and Next-Generation Protein Sequencing. This news page aggregates company-issued updates and market-moving announcements so readers can follow how Quantum-Si’s benchtop protein sequencing platform, chemistry kits, and data analysis tools are evolving over time.
Recent Quantum-Si news has highlighted product launches such as the V4 Sequencing Kit, which the company reports improves sequencing coverage through additional amino acid recognition, specialized enzymes, and enhanced algorithms. The company has also announced a Version 3 Library Preparation Kit designed for lower protein input and detection of low-abundance proteins, along with data analysis enhancements that unlock detection of additional amino acids and improve peptide alignment and protein inference.
Investors and researchers can use this page to track updates on Quantum-Si’s Proteus platform development, including prototype sequencing milestones, technology roadmap disclosures, and plans related to amino acid coverage, controlled cleavage chemistry, and post-translational modification methods. Financial news items, such as quarterly earnings releases, capital raising transactions, and lease or other material agreements disclosed via Form 8-K, also appear in this feed.
In addition, the news stream captures corporate governance and human capital updates, including inducement grants under the company’s 2023 Inducement Equity Incentive Plan, investor conference participation, and Investor & Analyst Day events. Bookmark this page to review Quantum-Si’s official press releases and regulatory news in one place, with a focus on developments that shape the company’s proteomics technology, commercialization efforts, and capital markets activity.
Quantum-Si (NASDAQ: QSI) has announced key leadership appointments to enhance its commercial and operational capabilities as it scales its innovative Platinum™ protein sequencing platform. New roles include Katherine Atkinson as Senior VP of Demand Generation, Alex Hutcheson as Senior VP of Sales, Christine Nishiyama as VP of Supply Chain, and Dr. John Vieceli as VP of Algorithms. These executives bring extensive experience from notable firms, which is expected to drive growth in the company's emerging customer base. The advancements align with Quantum-Si's strategy to disseminate proteomic data through its unique single-molecule sequencing technology, aiming to impact various scientific disciplines in drug discovery and biotechnology.
Quantum-Si Incorporated (NASDAQ: QSI), known as The Protein Sequencing Company, will report its financial results for Q1 2023 on May 11, 2023, at 4:30 PM ET. The announcement includes a conference call for management to discuss the results and provide a business update. Interested parties can join the live webcast or register online for a dial-in number. Quantum-Si is pioneering in the proteomics sector, utilizing a unique semiconductor chip for next-generation single-molecule protein sequencing, impacting drug discovery and diagnostics.
Quantum-Si Incorporated (NASDAQ: QSI), known as The Protein Sequencing Company™, will present a new method for detecting arginine post-translational modifications (PTMs) using its innovative Platinum™ single-molecule protein sequencing platform at the AACR Annual Meeting 2023. Scheduled from April 14-19 in Orlando, Florida, Dr. Kenneth Skinner will showcase the findings on April 18 from 1:30-5:00 p.m. The results suggest that single-molecule sequencing could outperform traditional methods like mass spectrometry, which often struggle with low abundance and mass differences. This advancement could enhance biomarker development and drug discovery in cancer research. With its compact design and competitive price point of $70,000, Platinum aims to revolutionize proteomics research.
Quantum-Si Incorporated (NASDAQ: QSI), known as The Protein Sequencing Company, announced its participation in the B. Riley Securities' Life Sciences Tools Conference on April 6, 2023. The event focuses on how proteomics and AI advancements can enhance drug discovery. Patrick Schneider, President and COO, will join a panel discussion at 10:30 AM ET, while CEO Jeff Hawkins and Dr. Schneider will engage in a fireside chat at 2:30 PM ET. Interested parties can access live and archived webcasts from the Investors section of the Quantum-Si website.
Quantum-Si (Nasdaq: QSI) reported its Q4 and FY 2022 results, highlighting a net loss of $33.1 million for Q4 and $132.4 million for the full year. The company launched its Platinum™ protein sequencing system and started shipments in Q1 2023. It has a projected cash runway extending into 2026, with $351.3 million in cash and equivalents as of year-end 2022. Key partnerships were formed, including collaborations with Aviva Systems Biology and Biovista. R&D expenses increased significantly, totaling $72.1 million for the year, largely due to personnel costs and product development. Adjusted EBITDA was negative $100.6 million for 2022.
Quantum-Si Incorporated (NASDAQ: QSI), known as The Protein Sequencing CompanyTM, will participate in the 43rd Annual Cowen Health Care Conference in Boston, MA, from March 6-8, 2023. Management will present on March 7, 2023, at 9:10 AM ET. A live and archived webcast of the presentation will be accessible in the Investors section of the Quantum-Si website.
Quantum-Si focuses on advancing proteomics technology through its innovative semiconductor chip, intended to enhance single-molecule protein sequencing and promote drug discovery and diagnostics.
Quantum-Si Incorporated (QSI), known as The Protein Sequencing Company, will report its financial results for Q4 and full-year 2022 on March 6, 2023, before the market opens. The company will host a conference call at 8:30 AM ET on the same day to discuss these results along with a business update. Quantum-Si focuses on innovative proteomics technology, utilizing a unique semiconductor chip aimed at advancing drug discovery and diagnostics beyond traditional DNA sequencing methods. Further details and a replay of the call will be accessible through the company's website.
Quantum-Si Incorporated (NASDAQ: QSI) has announced the commencement of commercial shipments for its Platinum protein sequencing system. The company formed partnerships with Aviva Systems Biology and Biovista to enhance its protein sequencing research capabilities. Additionally, Quantum-Si reaffirmed its commitment to financial discipline, aiming to extend its cash runway beyond 2024. CEO Jeff Hawkins highlighted the launch as a pivotal transition from technology development to market delivery. The company will present updates at the 41st Annual J.P. Morgan Healthcare Conference on January 12.
Quantum-Si (NASDAQ: QSI) has announced a partnership with Aviva Systems Biology to develop protein enrichment kits aimed at enhancing protein sequencing capabilities. These kits will integrate with existing workflows, allowing researchers to investigate proteoforms through Quantum-Si's Platinum protein sequencing platform. CEO Jeff Hawkins emphasized the importance of protein function in understanding biological processes, while Aviva's President Kevin Harvey highlighted the collaboration's potential to accelerate discoveries in protein research.
Quantum-Si Incorporated (NASDAQ: QSI) announced a partnership with Biovista to enhance drug discovery through advanced protein sequencing and AI visualization technology. This collaboration aims to speed up protein drug target discovery by allowing researchers to analyze connections between proteins, diseases, and drug mechanisms. The integration of Biovista's VIZIT™ tool into Quantum-Si's cloud-based suite enhances proteomic workflows, facilitating the discovery of new therapeutic targets and biomarkers.
FAQ
What is the current stock price of Quantum-Si Incorporated (QSI)?
What is the market cap of Quantum-Si Incorporated (QSI)?
